AZN AstraZeneca PLC

Seven hundred thousand seniors have already started GLP-1s through Medicare, and AstraZeneca just pushed a once-daily pill into late-stage trials. Before you plan your budget around a $50 copay, there are two deadlines that could change everything.

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant read ivonescimab correctly.

AstraZeneca (LSE:AZN) reported that the FDA has granted Priority Review to a supplemental Biologics License Application for IMFINZI with enfortumab vedotin in muscle-invasive bladder cancer. The application targets patients who are ineligible for or decline cisplatin-based chemotherapy, a group with limited treatment choices. Priority Review shortens the FDA review timeline for this regimen, reflecting the agency's view that it may offer a meaningful clinical advance. The Priority Review...

AstraZeneca (LSE:AZN) has just filed a New Drug Application with the US FDA for combining ORPATHYS and TAGRISSO in a specific form of advanced non small cell lung cancer after EGFR TKI treatment. AstraZeneca’s latest oncology filings land after a choppy run for the ticker, with the share price down 10.29% over 90 days and 8.56% year to date. At the same time, the 1 year total shareholder return of 13.04% and 5 year total shareholder return of 55.73% point to a still solid longer term story,...

Astrazeneca (AZN) closed at $164.21 in the latest trading session, marking a -1.17% move from the prior day.

Summit Therapeutics stock jumped Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.

AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in AZN shares today? Let’s find out!

AstraZeneca's (AZN) $2 billion investment in Summit Therapeutics (SMMT) is a "win-win" and potential

A preferred-equity investment secures collaboration access without the cost and integration risk of an acquisition.

The liquidation auctioneer Liquidity Services is closing in on a buy point. The stock is up roughly 45% this year.

The companies will start by testing ivonescimab with an AstraZeneca ADC in gastrointestinal cancers

SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.

The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad

AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the

Healthcare stocks edged higher Friday afternoon, with the NYSE Healthcare Index and the State Street

SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.

AstraZeneca PLC (NYSE:AZN) announced on September 11, 2026, that its Phase III SERENA-4 trial evaluating Etcamah (camizestrant) in combination with palbociclib failed to meet its primary endpoint of progression-free survival (PFS) in patients with upfront first-line ER-positive, HER2-negative advanced breast cancer. While the regimen demonstrated numerical improvement over standard anastrozole plus palbociclib, it did not […]

Rising UK borrowing costs, highlighted by the recent jump in 10 year gilt yields ahead of the next budget, are forcing investors to think harder about where future growth could come from. That is one reason artificial intelligence in healthcare is getting more attention. This piece looks at three UK focused AI healthcare stocks from our screener that aim to tap into this shift and explains what each one offers. The three stocks covered below are just a sample, and the full screen surfaced 5...

ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.

IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.

AZN's Trixeo wins EU approval for asthma, adding an indication backed by phase III data showing improved lung function.

All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively t

Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock Price Target: $47What Happened?Novo Nordisk (NVO) stock dropped sharply on Monday after the company laid out new long-term goals that failed to convince investors it can hold its ground against fast-growing rivals in the weight loss drug market.

Xi Jinping and Donald Trump have much to beef about when they meet in Washington this week. One topic on which the leaders of the world's biggest...

Novo is open to the idea of upgrading its New York listing as part of efforts to boost the Danish weight-loss drugmaker’s profile in the US and...

AstraZeneca (LSE:AZN) received positive opinions from the EMA's CHMP for Enhertu and Klygefa in the European Union. The CHMP backed Enhertu as an adjuvant treatment option for early-stage HER2-positive breast cancer with high risk of recurrence. The committee also supported Klygefa as an add-on therapy for generalised myasthenia gravis, targeting patients with a rare autoimmune condition. These fresh CHMP views on Enhertu and Klygefa sit alongside a wider set of AstraZeneca developments...

Britain’s biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research.

LONDON, Sept 22 (Reuters) - European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings ‌on Tuesday that the continent's pharmaceutical industry risks losing out to the ‌United States and China. Cash-strapped European governments have been under pressure for some time from lobby groups ​and drugmakers to rethink how they attract, nurture, value and pay for innovative medicines to avoid falling behind in an increasingly com

AstraZeneca has ridden a strong five year share price run and a steady stream of oncology and respiratory trial updates, which raises a simple question for investors who care about valuation. Is the current price around £125.60 broadly in line with what the company’s cash flows can support, or has sentiment run ahead of the underlying economics? Over the past 5 years, AstraZeneca has delivered a share price gain of 62.7%, which puts a lot of weight on whether its future cash generation can...

AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo’s Enhertu has been cleared for use by England’s National Health Service (NHS) for patients with HER2-low metastatic breast cancer, reversing an earlier NICE decision that rejected funding on cost-effectiveness grounds. NICE’s revised recommendation follows changes to drug valuation methods and a U.S.-UK agreement aimed at aligning medicine prices. Around […]

In the latest trading session, Astrazeneca (AZN) closed at $168.1, marking a +1.22% move from the previous day.

Guardant Health has also earned a spot on the Investor's Business Daily Leaderboard. Earlier this month, the FDA approved Guardant360 CDx as a companion diagnostic for Etcamah from AstraZeneca in advanced or metastatic breast cancer. Guardant360 CDx is the first FDA-approved liquid biopsy CDx for longitudinal testing in breast cancer.

AstraZeneca's Klygefa wins a positive EU recommendation for AChR-positive gMG, backed by phase III data and a convenient once-weekly treatment option.

Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...

European equities traded in the US as American depositary receipts started the week higher on Monday

AZN and MRK bring distinct oncology strengths, growth plans, pipeline opportunities and patent-related challenges to the table.

The drugmaker expects growth in line with industry peers as it works to rebuild its pipeline beyond obesity

AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.

AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.

AstraZeneca (LSE:AZN) and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy. Long-term follow-up data for TAGRISSO indicated eight-year survival benefits in early-stage EGFR-mutated lung cancer patients already on treatment protocols. Tozorakimab emerged as the first biologic to show efficacy in reducing exacerbations across a broad chronic obstructive pulmonary disease population in...

On September 8, 2026, CNBC reported that AstraZeneca PLC (NYSE:AZN) released full results from two successful late-stage trials of tozorakimab, an experimental drug for chronic obstructive pulmonary disease. It shows the treatment reduced moderate and severe flare-ups by roughly 30% across a broad patient population, reinforcing the company’s forecast that the drug could generate more […]

NHS reimbursement expands patient access, but confidential pricing prevents a reliable revenue calculation.

On September 5, 2026, Bloomberg reported that the FDA granted accelerated approval to AstraZeneca PLC (NYSE:AZN)’s camizestrant, sold as Etcamah, for a genetically driven form of metastatic breast cancer. Even though an FDA advisory panel voted in April that the drug lacked patient benefit. The approval covers use alongside a CDK4/6 inhibitor for patients with […]

Morgan Stanley just reframed the revenue story for Tempus AI in a way that management's own guidance never fully captured, and the market is now scrambling to catch up with what reimbursement clarity actually means for the bottom line.

Sir Keir Starmer’s decision to invite Sir Pascal Soriot, AstraZeneca’s chief executive, to Beijing at the beginning of the year was a textbook piece of modern diplomacy.

Sir Keir Starmer’s decision to invite Sir Pascal Soriot, AstraZeneca’s chief executive, to Beijing at the beginning of the year was a textbook piece of modern diplomacy.